Skip to main content
Events

Step Pharma to present a poster on STP938 at 12th International Congress on AutoImmunity

By May 21, 2021July 12th, 2022No Comments

EVENT

Paris, France, France, May 21, 2021

Step Pharma will present at the 12th International Congress on AutoImmunity. Listen to our poster presentation on Monday 31st May.

About Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of cancer types. The company has identified several inhibitors of CTPS1, with the most advanced, STP938, being prepared for clinical studies in haematological malignancies.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in Saint-Genis-Pouilly, France, and is supported by a strong investor base led by Kurma Partners and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares and InnoBio2 Fund), Pontifax, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute.

For more information please contact

Step Pharma
Andrew Parker, Chief Executive Officer
contact@step-ph.com

+ LEARN MORE